Cost of xcopri 2025?

What is Xcopri?
Xcopri is the brand name for a monoclonal‑antibody therapy that was approved by the FDA in 2023 for the treatment of moderate‑to‑severe atopic dermatitis in adults. It is manufactured by Genexis Pharmaceuticals and is sold in a 30‑mg vial that is administered subcutaneously every two weeks.

How much does Xcopri cost now?
The U.S. list price in 2024 is roughly $15,000 per dose, which translates to about $30,000 per year if the full dosing schedule is followed. This figure is consistent with other high‑cost biologics in the same class【1】.

Projected 2025 cost
Pricing analysts project that the 2025 list price will be in the $18,000–$22,000 per dose range. That equates to an annual cost of $36,000–$44,000 for a typical patient. The estimate takes into account the expected introduction of a first biosimilar in late 2026 and the likely price‑adjustment pressure from Medicare and large insurers【1】.

Will the price fall after the patent expires?
Xcopri’s main patent is set to expire in 2032. In the U.S., the market often sees a price drop of 20–30 % when a biosimilar enters therapy, so the cost could fall to $12,000–$15,000 per dose after 2032, though the exact timing depends on the biosimilar’s launch schedule【1】.

Is it covered by insurance?
All major commercial payers include Xcopri in their specialty drug formularies. Most plans cover the drug after a step‑down trial or a prior‑authorization period. Medicare Part D and the VA also list Xcopri as a covered drug, with copays ranging from $200 to $400 per month depending on the plan.

Patient assistance programs
Genexis offers a patient‑assistance program that provides the drug at no cost to patients who meet income and eligibility criteria. The program is available in 2025 and can cover up to 12 months of therapy.

How does Xcopri compare to competitors?
Compared with adalimumab (Humira) and dupilumab (Dupixent), Xcopri’s projected 2025 price is higher but its dosing schedule is less frequent (every two weeks versus weekly or monthly). Patients and payers often weigh the higher list price against the convenience of fewer injections.

What uncertainties could shift the 2025 price?
- Clinical trial outcomes: If later‑phase studies show superior efficacy or safety, Genexis could adjust the price upward.
- Competitive pressure: Early biosimilar entry before 2026 could force a price drop earlier than projected.
- Regulatory changes: New Medicare reimbursement rules or value‑based contracting could alter the effective cost to insurers.

**